| Budget Amount *help |
¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000)
Fiscal Year 2021: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2020: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2019: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2018: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
|
|---|
| Outline of Final Research Achievements |
In this study, we aimed to explore prognostic factors for patients with unresectable pancreatic cancer who received chemotherapy (n=153) or palliative care alone (n=43), based on clinical data such as age, gender, performance status (PS), pretreatment laboratory results (leukocytes, neutrophils, lymphocytes, platelets, albumin, CRP, CA19-9, CEA), tumor factors and survival time from diagnosis.
Univariate analysis identified liver metastasis, peritoneal metastasis, neutrophil count, albumin level, CRP, NLR, CAR, CEA, and CA19-9 as prognostic factors in the chemotherapy group, while PS, lung metastasis, peritoneal metastasis, CRP, CAR, CEA, and CA19-9 in the palliative care group.
Multivariate analysis revealed that liver metastasis (p<0.001), NLR (p<0.001) and CA19-9 (p=0.036) were independent prognostic factors in the chemotherapy group, whereas lung metastasis (p=0.004), peritoneal metastasis (p=0.014) and CAR (p=0.003) for palliative care alone group.
|
